UPDATE: Piper Jaffray Downgrades Trius Therapeutics Following Cubist Acquisition
July 31, 2013 at 11:20 AM EDT
In a report published on Wednesday, Piper Jaffray analyst Edward Tenthoff downgraded Trius Therapeutics (NASDAQ: TSRX ) from Overweight to Neutral and raised the price target from $11.00 to $14.82. In the report, Piper Jaffray stated, "Yesterday, Cubist (CBST) announced the acquisition of Trius for $13.50 in cash plus one non-tradeable $2.00
